CG Oncology Statistics
Total Valuation
CG Oncology has a market cap or net worth of $6.79 billion. The enterprise value is $5.77 billion.
| Market Cap | 6.79B |
| Enterprise Value | 5.77B |
Important Dates
The last earnings date was Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CG Oncology has 88.64 million shares outstanding. The number of shares has increased by 14.15% in one year.
| Current Share Class | 88.64M |
| Shares Outstanding | 88.64M |
| Shares Change (YoY) | +14.15% |
| Shares Change (QoQ) | +4.36% |
| Owned by Insiders (%) | 0.92% |
| Owned by Institutions (%) | 93.92% |
| Float | 64.45M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,088.08 |
| Forward PS | 547.31 |
| PB Ratio | 6.61 |
| P/TBV Ratio | 6.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 924.39 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 22.22, with a Debt / Equity ratio of 0.01.
| Current Ratio | 22.22 |
| Quick Ratio | 21.78 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -26.41% and return on invested capital (ROIC) is -18.47%.
| Return on Equity (ROE) | -26.41% |
| Return on Assets (ROA) | -17.67% |
| Return on Invested Capital (ROIC) | -18.47% |
| Return on Capital Employed (ROCE) | -24.33% |
| Weighted Average Cost of Capital (WACC) | 5.51% |
| Revenue Per Employee | $43,859 |
| Profits Per Employee | -$1.58M |
| Employee Count | 142 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +219.86% in the last 52 weeks. The beta is 0.23, so CG Oncology's price volatility has been lower than the market average.
| Beta (5Y) | 0.23 |
| 52-Week Price Change | +219.86% |
| 50-Day Moving Average | 67.91 |
| 200-Day Moving Average | 58.06 |
| Relative Strength Index (RSI) | 60.25 |
| Average Volume (20 Days) | 814,926 |
Short Selling Information
The latest short interest is 12.11 million, so 13.66% of the outstanding shares have been sold short.
| Short Interest | 12.11M |
| Short Previous Month | 12.07M |
| Short % of Shares Out | 13.66% |
| Short % of Float | 18.78% |
| Short Ratio (days to cover) | 9.39 |
Income Statement
In the last 12 months, CG Oncology had revenue of $6.23 million and -$224.38 million in losses. Loss per share was -$2.72.
| Revenue | 6.23M |
| Gross Profit | -161.54M |
| Operating Income | -252.62M |
| Pretax Income | -224.38M |
| Net Income | -224.38M |
| EBITDA | -249.66M |
| EBIT | -252.62M |
| Loss Per Share | -$2.72 |
Balance Sheet
The company has $1.03 billion in cash and $8.82 million in debt, with a net cash position of $1.02 billion or $11.50 per share.
| Cash & Cash Equivalents | 1.03B |
| Total Debt | 8.82M |
| Net Cash | 1.02B |
| Net Cash Per Share | $11.50 |
| Equity (Book Value) | 1.03B |
| Book Value Per Share | 11.65 |
| Working Capital | 1.00B |
Cash Flow
In the last 12 months, operating cash flow was -$178.47 million and capital expenditures -$876,000, giving a free cash flow of -$179.34 million.
| Operating Cash Flow | -178.47M |
| Capital Expenditures | -876,000 |
| Depreciation & Amortization | 2.96M |
| Net Borrowing | n/a |
| Free Cash Flow | -179.34M |
| FCF Per Share | -$2.02 |
Margins
| Gross Margin | n/a |
| Operating Margin | -4,056.18% |
| Pretax Margin | -3,602.68% |
| Profit Margin | n/a |
| EBITDA Margin | -4,008.72% |
| EBIT Margin | -4,056.18% |
| FCF Margin | n/a |
Dividends & Yields
CG Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.15% |
| Shareholder Yield | -14.15% |
| Earnings Yield | -3.31% |
| FCF Yield | -2.65% |
Analyst Forecast
The average price target for CG Oncology is $91.08, which is 18.83% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $91.08 |
| Price Target Difference | 18.83% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | 363.87% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CG Oncology has an Altman Z-Score of 41.42 and a Piotroski F-Score of 3.
| Altman Z-Score | 41.42 |
| Piotroski F-Score | 3 |